Interpace Biosciences Current Valuation vs. Price To Book
| IDXGDelisted Stock | USD 2.20 0.00 0.00% |
For Interpace Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Interpace Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Interpace Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Interpace Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Interpace Biosciences over time as well as its relative position and ranking within its peers.
Interpace |
Interpace Biosciences Price To Book vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Interpace Biosciences's current stock value. Our valuation model uses many indicators to compare Interpace Biosciences value to that of its competitors to determine the firm's financial worth. Interpace Biosciences is rated below average in current valuation category among its peers. It is rated second overall in price to book category among its peers . The ratio of Current Valuation to Price To Book for Interpace Biosciences is about 1,168,073 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Interpace Biosciences' earnings, one of the primary drivers of an investment's value.Interpace Current Valuation vs. Competition
Interpace Biosciences is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 4.44 Billion. Interpace Biosciences adds roughly 11.72 Million in current valuation claiming only tiny portion of equities under Health Care industry.
Interpace Price To Book vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Interpace Biosciences |
| = | 11.72 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Interpace Biosciences |
| = | 10.04 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Interpace Price To Book Comparison
Interpace Biosciences is currently under evaluation in price to book category among its peers.
Interpace Biosciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Interpace Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Interpace Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Interpace Biosciences' change in net profit over the period of time. It can combine multiple indicators of Interpace Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. Interpace Diag operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 147 people.
Interpace Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Interpace Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Interpace Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Interpace Biosciences' important profitability drivers and their relationship over time.
Use Interpace Biosciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Interpace Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Interpace Biosciences will appreciate offsetting losses from the drop in the long position's value.Interpace Biosciences Pair Trading
Interpace Biosciences Pair Trading Analysis
The ability to find closely correlated positions to Interpace Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Interpace Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Interpace Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Interpace Biosciences to buy it.
The correlation of Interpace Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Interpace Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Interpace Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Interpace Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Interpace Biosciences position
In addition to having Interpace Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Synthetics Thematic Idea Now
Synthetics
Companies involved in production of silicon and other synthetic products . The Synthetics theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Synthetics Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Interpace OTC Stock
If you are still planning to invest in Interpace Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Interpace Biosciences' history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Commodity Directory Find actively traded commodities issued by global exchanges |